Pfizer, FDA, BioMarin, worst CEO of 2025: Readout Newsletter
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
Pharma’s ‘Dr. Optimistic’ is worried about the industry’s future
In July 2006, The New York Times sent young reporter Alex Berenson to Pfizer to interview me about…
Mutual mistrust: FDA staff wary as Høeg becomes top drug regulator
WASHINGTON — In 2008, Tracy Beth Høeg, then a resident physician and ultramarathon runner, expressed dismay at vice…
‘Remarkable’ drug results against an aggressive leukemia – statnews.com
‘Remarkable’ drug results against an aggressive leukemia statnews.comDr Jen on the Efficacy of an All-Oral, Revumenib-Containing Regimen in AML OncLiveAll-Oral…
Embattled FDA official defends vaccine plan in closed-door remarks
Damian Garde is a reporter at large, live and feature journalism, covering the global drug industry and contributing…
FDA reviewers didn’t get to vote on first priority voucher drug
WASHINGTON — The Food and Drug Administration has promised companies that earn a Commissioner’s National Priority Voucher a one-…
J&J, aluminum and vaccines, NIH: Readout Newsletter
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
Countries used to test drugs often don’t see the approved medicines, study finds
Numerous medicines are not accessible in many of the countries where they were tested before approval by the…
China’s WuXi AppTec, after evading threat of U.S. ban, comes out ahead
For nearly two years, WuXi AppTec, the Chinese contract research giant with extensive ties with U.S. biotech and…
New FDA priority review vouchers go to Lilly, Novo, Vertex
WASHINGTON — The Food and Drug Administration on Thursday announced the second batch of companies being granted a “Commissioner’s…
Big Pharma’s ‘patient advocacy’ needs to remember patients’ needs
Every year, pharmaceutical companies spend millions on “patient advocacy.” At its best, this supports families, advances science, and…
FDA’s top drug regulator, George Tidmarsh, put on leave amid probe
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…